Evogene Cash Flow Conversion Efficiency

Latest as of September 2025: -0.220x

Evogene cash flow conversion efficiency. Based on the latest financial reports, Evogene (EVGN) has a cash flow conversion efficiency ratio of -0.220x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-3.79 Million ≈ $-10.16K USD) by net assets (ILA17.25 Million ≈ $46.25K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Evogene (2008–2024)

Cash flow conversion efficiency of Evogene from 2008 to 2024. This chart illustrates how Evogene's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Evogene stock price for real-time trading data and today's change.

Evogene Cash Flow Conversion Ratio Explained

Evogene cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Evogene Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Evogene ranked by their cash flow conversion efficiency. Also see EVGN market cap overview for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Aptevo Therapeutics Inc NASDAQ:APVO	-0.903x
Locafy Ltd NASDAQ:LCFY	-0.083x
Cyclerion Therapeutics Inc NASDAQ:CYCN	-0.282x
The Income & Growth VCT LSE:IGV	-0.016x
Hedera Group publ AB ST:HEGR	0.021x
Ab Dynamics LSE:ABDP	0.032x
Catheter Precision Inc. NYSE MKT:VTAK	-0.227x
Crown LNG Holdings Limited Warrants NASDAQ:CGBSW	-0.192x

Annual Cash Flow Conversion Efficiency for Evogene (2008–2024)

The table below shows the annual cash flow conversion efficiency of Evogene from 2008 to 2024. Review cash generation quality of Evogene to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA14.84 Million ≈ $39.78K	ILA-19.70 Million ≈ $-52.82K	-1.328x	-76.50%
2023-12-31	ILA28.68 Million ≈ $76.90K	ILA-21.58 Million ≈ $-57.85K	-0.752x	-10.52%
2022-12-31	ILA34.79 Million ≈ $93.27K	ILA-23.68 Million ≈ $-63.48K	-0.681x	-73.77%
2021-12-31	ILA63.42 Million ≈ $170.03K	ILA-24.84 Million ≈ $-66.59K	-0.392x	-14.17%
2020-12-31	ILA56.88 Million ≈ $152.50K	ILA-19.51 Million ≈ $-52.32K	-0.343x	-18.97%
2019-12-31	ILA60.22 Million ≈ $161.44K	ILA-17.36 Million ≈ $-46.55K	-0.288x	+4.32%
2018-12-31	ILA50.31 Million ≈ $134.87K	ILA-15.16 Million ≈ $-40.65K	-0.301x	-31.26%
2017-12-31	ILA69.38 Million ≈ $186.00K	ILA-15.93 Million ≈ $-42.71K	-0.230x	-71.40%
2016-12-31	ILA87.29 Million ≈ $234.02K	ILA-11.69 Million ≈ $-31.35K	-0.134x	-12.02%
2015-12-31	ILA103.75 Million ≈ $278.16K	ILA-12.41 Million ≈ $-33.26K	-0.120x	-56.06%
2014-12-31	ILA116.08 Million ≈ $311.21K	ILA-8.89 Million ≈ $-23.85K	-0.077x	-81.38%
2013-12-31	ILA124.75 Million ≈ $334.44K	ILA-5.27 Million ≈ $-14.13K	-0.042x	-7.98%
2012-12-31	ILA48.26 Million ≈ $129.38K	ILA-1.89 Million ≈ $-5.06K	-0.039x	-188.20%
2011-12-31	ILA48.09 Million ≈ $128.92K	ILA2.13 Million ≈ $5.72K	0.044x	-3.18%
2009-12-31	ILA19.34 Million ≈ $51.85K	ILA886.00K ≈ $2.38K	0.046x	-96.51%
2008-12-31	ILA9.61 Million ≈ $25.76K	ILA12.61 Million ≈ $33.80K	1.312x	--

About Evogene

TA:EVGN Israel Biotechnology

Market Cap

$2.24 Million

ILA836.95 Million ILA

Market Cap Rank

#29882 Global

#433 in Israel

Share Price

ILA96.00

Change (1 day)

-11.28%

52-Week Range

ILA96.00 - ILA409.10

All Time High

ILA33620.00